ArticleMaterials today. Bio2026
Bio-inspired spatiotemporal cascade reaction liposome for ferroptosis treatment following subarachnoid hemorrhage.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subarachnoid hemorrhage (SAH) is a type of stroke mainly caused by the bursting of brain aneurysms, releasing iron ions into the subarachnoid space and subsequently inducing ferroptosis. Despite the utilization of various ferroptosis-inhibiting pharmacological agents to enhance neurological outcomes post-SAH, challenges such as inadequate targeting and suboptimal drug utilization persist. In response to these limitations, we have developed a novel spatiotemporal cascade reaction liposome that recombinant proteins incorporating neuron-targeting peptides and the functional structural domain of ferroptosis suppressor protein 1 (FSP1) were immobilized on the external surface of liposomes, which were internally loaded with coenzyme Q10 (CoQ10) to construct FSP1-Lipo-CoQ10.The purpose of this study is to investigate the neuroprotective effects of FSP1-Lipo-CoQ10 following SAH. As a result, FSP1-loaded liposomes enable targeted delivery to neurons in the lesion area and increase FSP1 levels on the cell membrane. Among the three liposomal formulations, FSP1-Lipo-CoQ10 demonstrated the most potent anti-ferroptosis effects and the greatest improvement in neurological function. FSP1-Lipo-CoQ10 provides a new approach for the therapeutic management of ferroptosis post-SAH and ameliorates associated pathological conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.